TRUETIDE PLC

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. TRUETIDE PLC 2025-10-09 → present
2. BRAVEHEART INVESTMENT GROUP PLC 2003-04-07 → 2025-10-09

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

MAH, Chartered Accountants

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors, having reviewed the Group's and Company's budgets and plans, taking account of reasonably possible changes in trading performance, have a reasonable expectation that the Group and the Company have adequate resources to continue in operational existence for the foreseeable future and that it is therefore appropriate to continue to adopt the going concern basis in preparing the financial statements.”

Group structure

1. TRUETIDE PLC · parent
   1. Braveheart Investment Group Limited 100% · Scotland · Investment management
   2. Braveheart Academic Seed Funding GP Limited 100% · England · Investment management
   3. Ridings Holdings Limited 100% · England · Investment management
   4. The Ridings Early Growth Investment Company Limited 100% · England · Investment management
   5. Paraytec Limited 100% · England · Development of high performance specialist detectors

Significant events

• “On 25 June 2026, the Company reported that Paraytec and VosBio are in the early stages of a collaboration to develop a non-invasive test for the early detection of lung cancer in exhaled breath.”
• “On 5 June 2026, Image Scan announced a substantial contract to supply 25 of its ThreatScan® portable X-ray systems to a European government defence organisation for use in Explosive Ordnance Disposal operations.”
• “On 3 June 2026 it launched IB Nimble™ 2, a substantially upgraded secure platform (web, iOS and Android) for multidisciplinary clinical collaboration, tumour-board discussions and emergent care.”
• “On 9 June 2026, Imaging Biometrics announced publication of the Phase 1 Clinical Trial results of oral gallium maltolate (GaM) in recurrent glioblastoma... Imaging Biometrics intends to reactivate its Expanded Access Programme (EAP) to enrol up to 20 additional patients.”
• “The group sold Kirkstall Limited during the year, as well as some shares in Built Cybernetics plc (previously Aukett Swanke plc) and Image Scan Holdings plc in the year, resulting in a profit on disposal of £115,000.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.